Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Oak Street Health, Inc. ("Oak Street Health") announced today the appointment of
Brian Clem as Chief Operating Officer of the Company. Mr Clem's appointment in
this role will be effective as of January 1, 2022. In this new role, Mr. Clem
will continue to report to the Company's Chief Executive Officer. Mr. Clem has
served as the President of Oak Street Health since 2019, having joined the
company in 2015 as a Regional Vice President and subsequently being promoted to
Divisional President. Prior to joining Oak Street Health, Brian led the Medicare
Advantage business from 2013 until 2015 at IU Health Plans, which is part of the
Indiana University Health system. Prior to 2013, Brian served in leadership
roles at Eli Lilly & Co., a global pharmaceutical company, beginning in 2004.
Brian received an M.B.A. from Stanford University's Graduate School of Business
and a B.A. in Economics from Wabash College.
Mr. Clem succeeds Geoffrey Price who will become, as of January 1, 2022, the
Company's Chief Innovation Officer. Mr. Price will continue to serve on the
Company's Board of Directors. Mr. Price has served as the Company's Chief
Operating Officer and a member of the Company's Board since he co-founded the
Company in 2012. Prior to co-founding Oak Street Health, Mr. Price was a Project
Leader from 2012 until 2013 and a Consultant from 2010 to 2012 at Boston
Consulting Group. Mr. Price received an M.B.A. from Harvard Business School and
a B.S. in Engineering from the University of Illinois. Mr. Price will continue
to report, in this new role, to the Company's Chief Executive Officer.
Any material changes or amendments to Mr. Clem's or Mr. Price's compensation
arrangements in connection with these appointments have not yet been determined.
In accordance with Instruction 2 to Item 5.02 of Form 8-K, the Company intends
to file an amendment to this Current Report on Form 8-K if and when such
information is available.
Item 7.01 Regulation FD Disclosure
On December 29, 2021, the Company issued a press release announcing these
appointments as well as certain other leadership appointments. A copy of the
press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and
is incorporated herein by reference. The information reported in this Item 7.01
(including Exhibit 99.1) is furnished to and not "filed" with the Securities and
Exchange Commission for the purposes of the Securities Exchange Act of 1934, as
amended, and it shall not be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, except as shell be expressly set
forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit Description
99.1 Press Release Dated December 29 , 2021
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
2
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses